Quorum sensing inhibition selects for virulence and cooperation in Pseudomonas aeruginosa.
With the rising development of bacterial resistance the search for new medical treatments beyond conventional antimicrobials has become a key aim of public health research. Possible innovative strategies include the inhibition of bacterial virulence. However, consideration must be given to the evolutionary and environmental consequences of such new interventions. Virulence and cooperative social behaviour of the bacterium Pseudomonas aeruginosa rely on the quorum-sensing (QS) controlled production of extracellular products (public goods). Hence QS is an attractive target for anti-virulence interventions. During colonization, non-cooperating (and hence less virulent) P. aeruginosa QS-mutants, benefiting from public goods provided by wild type isolates, naturally increase in frequency providing a relative protection from invasive infection. We hypothesized that inhibition of QS-mediated gene expression removes this growth advantage and selection of less virulent QS-mutants, and maintains the predominance of more virulent QS-wild type bacteria. We addressed this possibility in a placebo-controlled trial investigating the anti-QS properties of azithromycin, a macrolide antibiotic devoid of bactericidal activity on P. aeruginosa, but interfering with QS, in intubated patients colonized by P. aeruginosa. In the absence of azithromycin, non-cooperating (and hence less virulent) lasR (QS)-mutants increased in frequency over time. Azithromycin significantly reduced QS-gene expression measured directly in tracheal aspirates. Concomitantly the advantage of lasR-mutants was lost and virulent wild-type isolates predominated during azithromycin treatment. We confirmed these results in vitro with fitness and invasion experiments. Azithromycin reduced growth rate of the wild-type, but not of the lasR-mutant. Furthermore, the lasR-mutant efficiently invaded wild-type populations in the absence, but not in the presence of azithromycin. These in vivo and in vitro results demonstrate that anti-virulence interventions based on QS-blockade diminish natural selection towards reduced virulence and therefore may increase the prevalence of more virulent genotypes in the Hospital environment. More generally, the impact of intervention on the evolution of virulence of pathogenic bacteria should be assessed.
Köhler
Thilo
T
Service of Infectious Diseases, University Hospital Geneva and Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland.
Perron
Gabriel G
GG
Buckling
Angus
A
van Delden
Christian
C
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017963:Azithromycin / Q000627:therapeutic use*; D016638:Critical Illness; D024881:Drug Resistance, Bacterial / Q000235:genetics; D019143:Evolution, Molecular; D006801:Humans; D009154:Mutation; D010919:Placebos; D018410:Pneumonia, Bacterial / Q000188:drug therapy / Q000382:microbiology; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000382:microbiology*; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000235:genetics / Q000472:pathogenicity; D053038:Quorum Sensing / Q000187:drug effects* / Q000235:genetics; D012121:Respiration, Artificial; D014132:Trachea / Q000382:microbiology; D014774:Virulence
D000900:Anti-Bacterial Agents; D010919:Placebos; D017963:Azithromycin
Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15876-81
17898171
Proc Biol Sci. 2003 Jan 7;270(1510):37-44
12590769
J Bacteriol. 1997 Sep;179(18):5756-67
9294432
Nature. 2001 Dec 13;414(6865):751-6
11742400
EMBO J. 2003 Aug 1;22(15):3803-15
12881415
Curr Opin Microbiol. 2003 Feb;6(1):56-60
12615220
J Antimicrob Chemother. 2003 Apr;51(4):939-45
12654753
J Bacteriol. 2000 Nov;182(21):5990-6
11029417
J Bacteriol. 2005 Jul;187(14):4875-83
15995202
Philos Trans R Soc Lond B Biol Sci. 2007 Jul 29;362(1483):1213-22
17360273
Antimicrob Agents Chemother. 2006 May;50(5):1680-8
16641435
Nature. 2007 Nov 15;450(7168):411-4
18004383
Proc Natl Acad Sci U S A. 2006 May 30;103(22):8487-92
16687478
Proc Biol Sci. 2001 May 7;268(1470):961-5
11370970
Clin Microbiol Infect. 2008 Apr;14(4):337-43
18190582
Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6339-44
19332772
J Antimicrob Chemother. 1993 May;31(5):681-8
8392997
Mol Microbiol. 2003 Dec;50(5):1477-91
14651632
Curr Biol. 2009 Feb 24;19(4):341-5
19230668
Trends Microbiol. 2002 Sep;10(9):401-5
12217504
Mol Microbiol. 2007 Apr;64(2):512-33
17493132
Antimicrob Agents Chemother. 2001 Jun;45(6):1930-3
11353657
BMC Biol. 2006 Jul 07;4:21
16827933
Emerg Infect Dis. 1998 Oct-Dec;4(4):551-60
9866731
Heredity (Edinb). 2008 May;100(5):484-8
18212805